AstraZeneca Submits Atacand For Heart Failure: First ARB To Show Mortality Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination use with ACE inhibitors will likely be an issue for the Atacand sNDA; the efficacy seen in AstraZeneca’s CHARM studies conflicts with the Val-HeFT data for Novatis’ angiotensin-II receptor blocker Diovan, which showed no added benefit.